Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

Support development and validation of biomarkers for neurological and neuromuscular disorders using human samples or data. Projects progress from candidate biomarker development or confirmation to validation for an intended clinical use, with milestones governing the transition between R61 and R33 phases. The combined project may last up to five years; budgets must reflect the work and are not capped by the NOFO. The next new-application deadline is 20 October 2026, at 5 p.m. in the applicant organisation’s local time.

Eligible US higher-education, nonprofit, for-profit and other organisations listed in the NOFO apply through their institution. Non-US organisations and non-US components of US organisations cannot apply. Required institutional registrations apply. Foreign components are allowed, but foreign subawards or subcontracts are not allowed under this NOFO.